Financial Comparison: OKYO Pharma (NASDAQ:OKYO) & X4 Pharmaceuticals (NASDAQ:XFOR)

OKYO Pharma (NASDAQ:OKYO) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, valuation and risk.

Valuation and Earnings

This table compares OKYO Pharma and X4 Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OKYO Pharma	N/A	N/A	-$13.27 million	N/A	N/A
X4 Pharmaceuticals	N/A	N/A	-$101.17 million	($0.60)	-2.05

Analyst Recommendations

This is a summary of recent ratings and recommmendations for OKYO Pharma and X4 Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OKYO Pharma	0	0	1	0	3.00
X4 Pharmaceuticals	0	1	1	0	2.50

OKYO Pharma presently has a consensus target price of $7.00, suggesting a potential upside of 400.00%. X4 Pharmaceuticals has a consensus target price of $3.00, suggesting a potential upside of 144.90%. Given OKYO Pharma’s stronger consensus rating and higher probable upside, equities analysts clearly believe OKYO Pharma is more favorable than X4 Pharmaceuticals.

Risk & Volatility

OKYO Pharma has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500. Comparatively, X4 Pharmaceuticals has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500.

Profitability

This table compares OKYO Pharma and X4 Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OKYO Pharma	N/A	N/A	N/A
X4 Pharmaceuticals	N/A	-170.10%	-65.44%

Insider & Institutional Ownership

3.0% of OKYO Pharma shares are held by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are held by institutional investors. 40.5% of OKYO Pharma shares are held by insiders. Comparatively, 1.1% of X4 Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

OKYO Pharma beats X4 Pharmaceuticals on 6 of the 8 factors compared between the two stocks.

About OKYO Pharma

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.